1. Home
  2. IAF vs NYXH Comparison

IAF vs NYXH Comparison

Compare IAF & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn Australia Equity Fund Inc.

IAF

abrdn Australia Equity Fund Inc.

HOLD

Current Price

$12.30

Market Cap

129.2M

Sector

Finance

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$3.29

Market Cap

152.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IAF
NYXH
Founded
1985
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Finance/Investors Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
129.2M
152.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
IAF
NYXH
Price
$12.30
$3.29
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$11.25
AVG Volume (30 Days)
54.8K
56.6K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
11.44%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$214.32
Revenue Next Year
N/A
$124.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.73
$2.76
52 Week High
$14.54
$8.64

Technical Indicators

Market Signals
Indicator
IAF
NYXH
Relative Strength Index (RSI) 55.71 42.77
Support Level $12.72 $2.76
Resistance Level $13.19 $3.32
Average True Range (ATR) 0.23 0.18
MACD 0.11 0.08
Stochastic Oscillator 98.58 44.89

Price Performance

Historical Comparison
IAF
NYXH

About IAF abrdn Australia Equity Fund Inc.

Aberdeen Australia Equity Fund Inc is a non-diversified closed-end investment management company. With a core focus on long-term capital appreciation, it invests predominantly in equity securities listed on the Australian Stock Exchange. Its secondary objective is current income, which it expects to derive from dividends and interest on Australian corporate and governmental securities. Its investment portfolio comprises diversified sectors that include Financials, Health Care, Materials, Information Technology, Real Estate, and other sectors.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: